Teduglutide
About
About Teduglutide
Teduglutide is a GLP-2 analog FDA-approved for short bowel syndrome (SBS) in adults and pediatric patients (brand: Gattex, NDA 203441). It promotes intestinal adaptation by stimulating crypt cell proliferation and reducing intestinal transit time, enabling some SBS patients to reduce or eliminate parenteral nutrition dependence. Note: teduglutide is the approved synthetic analog of the native GLP-2 peptide; GLP-2 (the unmodified native hormone) is a separate entry in this directory with RUO status.
Science
Mechanism of Action
Binds GLP-2 receptors on enteroendocrine L-cells and subepithelial myofibroblasts, triggering EGF, KGF, and IGF-1 release. This paracrine cascade promotes intestinal crypt cell proliferation, villus growth, and tight-junction integrity, increasing absorptive surface area. The alaGlu substitution at position 2 prevents DPP-4 cleavage, extending half-life from ~7 minutes (native GLP-2) to ~1.3 hours.
Dosing
Typical Protocol
0.05 mg/kg/day subcutaneous injection once daily. Dose individualized by weight; titration over weeks is standard. Colonoscopy required at baseline (polyp risk). Response assessment at 6 months; continued use requires demonstrable clinical benefit. Administered under physician supervision.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Regulatory
Legal Status in 2026
This compound has completed clinical trials and received formal FDA approval for one or more indications. It can be legally prescribed by licensed physicians, filled at any licensed pharmacy, and may be covered by insurance. Off-label use by physicians is also legal. This is the highest level of regulatory clearance available in the US.
Evidence
Evidence Tier
Supported by the clinical trial data required for FDA approval, representing the highest evidence bar. Safety and efficacy have been established in multiple phases of human clinical trials.
No verified providers offering Teduglutide yet
We audit new providers every week. Leave your email and we’ll let you know as soon as a Vial-verified provider starts offering Teduglutide.
Free. We’ll only email when there’s a real match.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.